tiprankstipranks
Trending News
More News >
Unity Biotechnology Inc (UBX)
NASDAQ:UBX

Unity Biotechnology (UBX) AI Stock Analysis

Compare
773 Followers

Top Page

UB

Unity Biotechnology

(NASDAQ:UBX)

Rating:31Underperform
Price Target:
Unity Biotechnology's overall score is weighed down by significant financial challenges, including persistent losses and negative equity. Technical analysis suggests a bearish trend with limited momentum. Valuation metrics reflect the unprofitability of the company. However, the recent strategic appointment to the Board provides a potential strategic advantage in its program development.
Positive Factors
Analyst Recommendation
The analyst's recommendation remains 'Outperform' with a price target of $6.00, indicating confidence in the stock's future performance.
Efficacy
UBX1325 patients gained 5.2 letters at week 24, and subsequently 5.5 letters at week 36, indicating vision improvement.
Market Potential
UBX1325 showed outperformance of aflibercept for patients with less aggressive disease, suggesting a prospective option for 2L treatment subsequent to standard of care anti-VEGF.
Negative Factors
Study Endpoint
The study missed the primary endpoint of non-inferiority vs aflibercept using the average of 20-week and 24-week BCVA letters change from baseline.
Study Imbalance
There were considerably more Vabysmo (faricimab) patients in the UBX1325 group, compared to aflibercept, reflecting a relevant imbalance.
Trial Results
The Phase 2B ASPIRE study of intravitreal foselutoclax (UBX1325) in diabetic macular edema patients did not meet the non-inferiority analysis specifically at the average of weeks 20 and 24 for the primary analysis.

Unity Biotechnology (UBX) vs. SPDR S&P 500 ETF (SPY)

Unity Biotechnology Business Overview & Revenue Model

Company DescriptionUnity Biotechnology, Inc., a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is Phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy. It also develops UBX1967 for the treatment of ophthalmologic diseases; UBX2050, a human anti-Tie2 agonist monoclonal antibody for the treatment of age-related eye diseases; and UBX2089, a a-Klotho hormone drug candidate for multiple neurology indications. The company was formerly known as Forge, Inc. and changed its name to Unity Biotechnology, Inc. in January 2015. Unity Biotechnology, Inc. was incorporated in 2009 and is headquartered in South San Francisco, California.
How the Company Makes MoneyUnity Biotechnology makes money through the development and commercialization of its therapeutic products targeting senescent cells. The company's revenue model primarily relies on milestone payments, licensing deals, and potential royalties from partnerships with larger pharmaceutical companies. Unity may also generate income from collaborations with other biotech firms or research institutions, which can provide funding for research and development activities. Additionally, the company might raise capital through public or private investments to support its ongoing research and clinical trials, which are crucial for bringing its products to market.

Unity Biotechnology Financial Statement Overview

Summary
Unity Biotechnology is struggling with financial challenges, reflected in its income statement, balance sheet, and cash flow. The lack of revenue growth, persistent losses, and negative equity highlight significant operational and financial risks. The company must focus on improving its revenue generation and managing expenses to achieve financial stability.
Income Statement
15
Very Negative
Unity Biotechnology has faced challenges with generating revenue, as indicated by repeated periods with zero or negative sales. The company has been unable to achieve profitability, with consistently negative EBIT and net income. This reflects ongoing operational difficulties and a need to establish sustainable revenue streams.
Balance Sheet
20
Very Negative
The balance sheet shows a concerning financial position, with negative stockholders' equity in the most recent period. The debt-to-equity ratio is not applicable due to negative equity, and the persistent decline in equity suggests financial instability. Despite a decrease in total assets, the company has managed to reduce its total liabilities.
Cash Flow
25
Negative
Operating cash flow remains negative, indicating ongoing cash burn. The free cash flow situation is concerning, showing no improvement. Although there is some cash inflow from investing activities, it is insufficient to offset the negative operating cash flow. The company's sustainability depends on its ability to manage cash effectively.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
0.000.000.00236.00K4.78M0.00
Gross Profit
227.00K0.00-19.70M-1.94M1.90M-3.45M
EBIT
-29.96M-31.17M-44.67M-57.57M-56.66M-93.93M
EBITDA
-32.32M-25.12M-37.28M-38.73M-54.67M-89.10M
Net Income Common Stockholders
-27.50M-25.99M-39.86M-57.75M-60.04M-91.87M
Balance SheetCash, Cash Equivalents and Short-Term Investments
16.93M23.23M43.20M94.80M88.08M97.70M
Total Assets
30.35M37.66M65.69M124.35M124.71M156.32M
Total Debt
18.68M23.54M26.99M47.36M51.56M58.98M
Net Debt
10.68M15.96M7.19M34.62M18.65M41.17M
Total Liabilities
30.55M31.17M37.29M57.50M65.14M73.44M
Stockholders Equity
-205.00K6.49M28.40M66.85M59.57M82.88M
Cash FlowFree Cash Flow
-22.04M-20.86M-37.10M-51.13M-45.26M-78.98M
Operating Cash Flow
-22.04M-20.86M-38.65M-51.03M-45.06M-78.33M
Investing Cash Flow
22.53M8.56M60.49M-24.55M39.31M-5.21M
Financing Cash Flow
77.00K77.00K-16.34M54.85M20.84M63.88M

Unity Biotechnology Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.68
Price Trends
50DMA
0.90
Negative
100DMA
1.39
Negative
200DMA
1.36
Negative
Market Momentum
MACD
-0.08
Negative
RSI
32.67
Neutral
STOCH
25.07
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UBX, the sentiment is Negative. The current price of 0.68 is below the 20-day moving average (MA) of 0.76, below the 50-day MA of 0.90, and below the 200-day MA of 1.36, indicating a bearish trend. The MACD of -0.08 indicates Negative momentum. The RSI at 32.67 is Neutral, neither overbought nor oversold. The STOCH value of 25.07 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for UBX.

Unity Biotechnology Risk Analysis

Unity Biotechnology disclosed 53 risk factors in its most recent earnings report. Unity Biotechnology reported the most risks in the “Finance & Corporate” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Unity Biotechnology Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.31B3.29-45.39%2.79%16.77%-0.07%
42
Neutral
$15.56M-122.28%
EQEQ
42
Neutral
$13.57M-88.32%-19.76%-13.20%
40
Underperform
$8.68M-64.18%1.00%
PMPMN
38
Underperform
$15.72M-19.56%98.61%
35
Underperform
$12.85M-58.78%-126.54%
UBUBX
31
Underperform
$11.72M-231.27%35.08%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
UBX
Unity Biotechnology
0.68
-0.94
-58.02%
CANF
Can-Fite BioPharma
1.10
-1.43
-56.52%
PMN
ProMIS Neurosciences
0.48
-1.23
-71.93%
EDSA
Edesa Biotech
1.83
-2.81
-60.56%
EQ
Equillium
0.38
-0.33
-46.48%
SNSE
Sensei Biotherapeutics
0.34
-0.33
-49.25%

Unity Biotechnology Corporate Events

Executive/Board ChangesBusiness Operations and Strategy
Unity Biotechnology Appoints Dr. Yehia Hashad to Board
Positive
Mar 10, 2025

On March 8, 2025, UNITY Biotechnology appointed Dr. Yehia Hashad to its Board of Directors and Science Committee. Dr. Hashad, an experienced ophthalmologist and executive at Bausch + Lomb, brings over 25 years of leadership in global research and development. His expertise is expected to aid UNITY in advancing its UBX1325 program for diabetic macular edema and other ophthalmologic treatments, potentially enhancing the company’s strategic positioning in the biotechnology sector.

Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.